Published in Blood on April 24, 2012
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol (2013) 11.58
Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood (2014) 2.84
Gene-engineered T cells for cancer therapy. Nat Rev Cancer (2013) 2.07
Advances in targeted genome editing. Curr Opin Chem Biol (2012) 1.97
Gene therapy returns to centre stage. Nature (2015) 1.95
Genome-editing Technologies for Gene and Cell Therapy. Mol Ther (2016) 1.41
megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering. Nucleic Acids Res (2013) 1.30
Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood (2013) 1.17
Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med (2013) 1.14
Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS One (2013) 1.14
A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev (2014) 1.14
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. J Natl Cancer Inst (2016) 1.11
Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol (2015) 1.09
Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. Mol Ther (2015) 1.04
Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res (2013) 1.01
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. Clin Cancer Res (2015) 1.00
T-cell immunotherapy: looking forward. Mol Ther (2014) 1.00
Human cell-based artificial antigen-presenting cells for cancer immunotherapy. Immunol Rev (2014) 0.93
New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell (2015) 0.93
Towards a commercial process for the manufacture of genetically modified T cells for therapy. Cancer Gene Ther (2015) 0.92
DNA transposon-based gene vehicles - scenes from an evolutionary drive. J Biomed Sci (2013) 0.89
TALEN and CRISPR/Cas Genome Editing Systems: Tools of Discovery. Acta Naturae (2014) 0.89
Engineering T cells for cancer: our synthetic future. Immunol Rev (2014) 0.88
Cornerstones of CRISPR-Cas in drug discovery and therapy. Nat Rev Drug Discov (2016) 0.88
Gene therapy for cancer: present status and future perspective. Mol Cell Ther (2014) 0.87
Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer. BioDrugs (2015) 0.86
A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy. Mol Ther (2015) 0.85
The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors. Chin J Cancer (2014) 0.85
Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. Nucleic Acids Res (2015) 0.85
Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma. Mol Ther (2016) 0.85
Selective immunotargeting of diabetogenic CD4 T cells by genetically redirected T cells. Immunology (2014) 0.84
Synthetic biology in cell-based cancer immunotherapy. Trends Biotechnol (2015) 0.84
Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. Pharmaceuticals (Basel) (2014) 0.84
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol (2012) 0.84
Engineering T cell function using chimeric antigen receptors identified using a DNA library approach. PLoS One (2013) 0.84
Genetically engineered T cells for the treatment of cancer. J Intern Med (2013) 0.83
Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res (2016) 0.82
Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids. Nat Methods (2017) 0.81
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol (2016) 0.81
Improved cell-penetrating zinc-finger nuclease proteins for precision genome engineering. Mol Ther Nucleic Acids (2015) 0.80
Genetically modified T cells to target glioblastoma. Front Oncol (2013) 0.80
T cell engineering as therapy for cancer and HIV: our synthetic future. Philos Trans R Soc Lond B Biol Sci (2015) 0.80
Progress and prospects for engineered T cell therapies. Br J Haematol (2014) 0.80
Chimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of Ras. Oncoimmunology (2015) 0.80
Challenges and opportunities of allogeneic donor-derived CAR T cells. Curr Opin Hematol (2015) 0.79
Generation of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors. Mol Ther Methods Clin Dev (2015) 0.79
Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells. Clin Exp Immunol (2015) 0.79
Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors. Mol Ther (2016) 0.79
Cytokine-induced killer (CIK) cells: from basic research to clinical translation. Chin J Cancer (2015) 0.78
Engineered T cells for cancer treatment. Cytotherapy (2013) 0.78
A genome editing primer for the hematologist. Blood (2016) 0.77
Adoptive T-cell therapy for Leukemia. Mol Cell Ther (2014) 0.77
Genetically modified T-cell therapy for osteosarcoma. Adv Exp Med Biol (2014) 0.77
Therapeutic T cell engineering. Nature (2017) 0.77
Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells. Mol Ther Methods Clin Dev (2017) 0.76
Sleeping Beauty transposon system for genetic etiological research and gene therapy of cancers. Cancer Biol Ther (2015) 0.76
Genome-Edited T Cell Therapies. Curr Stem Cell Rep (2017) 0.76
A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget (2017) 0.75
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. Front Immunol (2017) 0.75
Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials. Annu Rev Pathol (2016) 0.75
Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective. Mol Ther (2017) 0.75
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond. Trends Mol Med (2017) 0.75
Generation of Genetically Engineered Precursor T-Cells From Human Umbilical Cord Blood Using an Optimized Alpharetroviral Vector Platform. Mol Ther (2016) 0.75
Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy. Haematologica (2016) 0.75
Antibody-based therapeutics for the treatment of human B cell malignancies. Curr Allergy Asthma Rep (2013) 0.75
CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res (2016) 0.75
Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells. Mol Ther (2017) 0.75
Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications. Front Immunol (2016) 0.75
Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf. BioDrugs (2017) 0.75
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity. Front Immunol (2017) 0.75
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Genome editing with engineered zinc finger nucleases. Nat Rev Genet (2010) 18.88
Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol (2004) 17.54
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75
Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol (2008) 14.20
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 11.49
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood (2011) 7.49
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
A rapid and general assay for monitoring endogenous gene modification. Methods Mol Biol (2010) 6.77
Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proc Natl Acad Sci U S A (2008) 6.59
Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol (2010) 6.55
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol (2002) 5.49
HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science (1997) 4.58
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res (2006) 4.06
Transient cold shock enhances zinc-finger nuclease-mediated gene disruption. Nat Methods (2010) 3.59
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood (2010) 3.57
An inducible caspase 9 safety switch for T-cell therapy. Blood (2005) 2.93
Human T-cell receptor variable gene segment families. Immunogenetics (1995) 2.86
CARs on track in the clinic. Mol Ther (2011) 2.86
Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer (2004) 2.65
Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res (2008) 2.57
Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood (2010) 2.31
Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. Blood (2003) 2.31
Allo-HLA reactivity of virus-specific memory T cells is common. Blood (2010) 2.28
A transposon and transposase system for human application. Mol Ther (2010) 2.28
Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet (2002) 1.91
Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther (2007) 1.91
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med (2012) 1.87
Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood (2004) 1.75
piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther (2010) 1.64
Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood (2003) 1.55
Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res (2009) 1.55
Rapid, high-throughput engineering of sequence-specific zinc finger DNA-binding proteins. Methods Enzymol (2001) 1.49
Translating Sleeping Beauty transposition into cellular therapies: victories and challenges. Bioessays (2010) 1.42
Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med (2011) 1.37
Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther (2000) 1.34
Human CD62L- memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion. Blood (2004) 1.27
Sleeping beauty vector system moves toward human trials in the United States. Mol Ther (2008) 1.24
Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood (2006) 1.18
Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells. Exp Hematol (2007) 1.12
Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res (2010) 1.10
Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood (2003) 1.06
Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes. Bone Marrow Transplant (2006) 1.03
Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis (2004) 1.00
The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol (2010) 0.99
Mutation in the TCRα subunit constant gene (TRAC) leads to a human immunodeficiency disorder characterized by a lack of TCRαβ+ T cells. J Clin Invest (2011) 0.95
Off-the-shelf T-cell therapy. Blood (2010) 0.89
A TALE nuclease architecture for efficient genome editing. Nat Biotechnol (2010) 26.47
Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature (2005) 19.15
Genome editing with engineered zinc finger nucleases. Nat Rev Genet (2010) 18.88
An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol (2007) 17.80
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75
Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol (2008) 14.20
Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol (2009) 12.40
Knockout rats via embryo microinjection of zinc-finger nucleases. Science (2009) 12.33
Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol (2011) 11.76
Targeted genome editing across species using ZFNs and TALENs. Science (2011) 9.84
Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol (2007) 9.23
Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell (2010) 8.79
Knockout rats generated by embryo microinjection of TALENs. Nat Biotechnol (2011) 8.45
Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell (2005) 7.90
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med (2004) 7.10
Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet (2007) 6.93
A rapid and general assay for monitoring endogenous gene modification. Methods Mol Biol (2010) 6.77
Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proc Natl Acad Sci U S A (2008) 6.59
Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell (2011) 6.56
Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol (2010) 6.55
An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol (2011) 6.44
Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med (2002) 6.33
Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat Methods (2010) 6.00
Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases. Proc Natl Acad Sci U S A (2007) 5.93
Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science (2013) 5.64
Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol (2006) 5.58
Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst (2004) 5.39
Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol (2007) 5.36
Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science (2013) 5.34
Histone deimination antagonizes arginine methylation. Cell (2004) 5.19
Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res (2002) 4.99
Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature (2011) 4.92
In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature (2011) 4.81
Precise genome modification in the crop species Zea mays using zinc-finger nucleases. Nature (2009) 4.71
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol (2010) 4.67
Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med (2010) 4.23
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res (2006) 4.06
Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med (2003) 4.02
Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell (2011) 4.02
Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res (2010) 3.94
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol (2009) 3.89
Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity (2004) 3.81
FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell (2010) 3.80
Transient cold shock enhances zinc-finger nuclease-mediated gene disruption. Nat Methods (2010) 3.59
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood (2010) 3.57
Stable knockdown of microRNA in vivo by lentiviral vectors. Nat Methods (2008) 3.55